Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 361 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ARC Clear all
Completed Not applicable Interventional

A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients

NCT00002050
View directory record Official record
Conditions
HIV Infections
Interventions
Thymopentin
Drug
Lead sponsor
Immunobiology Research Institute
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Annandale, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients

NCT00002098
View directory record Official record
Conditions
HIV Infections
Interventions
Lentinan, Didanosine
Drug
Lead sponsor
AJI Pharma USA
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Francisco, California • Maitland, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)

NCT00002036
View directory record Official record
Conditions
HIV Infections
Interventions
Anti-HIV Immune Serum Globulin (Human)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 20, 2009 · Synced Oct 18, 2026, 4:09 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Addressing Root Causes for Gun Violence Prevention (ARC-GVP)

NCT05887973
View directory record Official record
Conditions
Violence, Adolescent, Firearm Injury, Aggression
Interventions
The T.R.I.G.G.E.R Project
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
14 Years to 24 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 18, 2026, 4:09 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Reconstruction Flaps for Nasal Surgical Wounds RCT

NCT04729231
View directory record Official record
Conditions
Surgical Wound
Interventions
Nasalis Sling Flap, Lobed Transposition Flap
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
19 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Not applicable Interventional

A Study of DTC in Patients With AIDS and AIDS Related Complex

NCT00002069
View directory record Official record
Conditions
HIV Infections
Interventions
Ditiocarb sodium
Drug
Lead sponsor
Merieux Institute
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 4:09 AM EDT
Active, not recruiting Phase 2 Interventional

Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)

NCT04609280
View directory record Official record
Conditions
Head and Neck Cancer, Oropharynx Cancer, Oropharyngeal Squamous Cell Carcinoma
Interventions
Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT)
Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Not applicable Interventional

Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection

NCT00000638
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Rifampin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
75
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Not applicable Interventional Results available

Combined Application of Electrical Stimulation and Volitional Contractions for Muscle Strengthening and Knee Pain Inhibition (Seated Study)

NCT02802878
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Hybrid Training using Electrodes and Joint Motion Sensors, Isokinetic Training with Isokinetic Dynamometer
Device
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
40 Years to 85 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Oct 18, 2026, 4:09 AM EDT
Recruiting No phase listed Observational

Augmented Renal Clearance in Neurocritical Care

NCT07410624
View directory record Official record
Conditions
TBI (Traumatic Brain Injury), Status Epilepticus, Bacterial Meningitis, Augmented Renal Clearance (ARC), Subarachnoid Hemorrhage, Aneurysmal, Ischemic Stroke, Intracerebral Hemorrhage
Interventions
Not listed
Lead sponsor
University of Alberta
Other
Eligibility
18 Years to 85 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Lexington, Kentucky • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Isoprinosine in Patients With Weakened Immune Systems and Lymph Node Disease

NCT00002296
View directory record Official record
Conditions
Lymphatic Disease, HIV Infections
Interventions
Inosine pranobex
Drug
Lead sponsor
Newport Pharmaceuticals International
Industry
Eligibility
18 Years to 50 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

A Study of Ribavirin in the Treatment of Patients With AIDS and AIDS-Related Problems

NCT00001015
View directory record Official record
Conditions
HIV Infections
Interventions
Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
5
States / cities
San Diego, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Not applicable Interventional

An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.

NCT00002133
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Itraconazole
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Berkeley, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

(Ro 24-2027) A Randomized, Double-Blind, Comparative Study of Dideoxycytidine (ddC) Versus Zidovudine (AZT) in Patients With AIDS or Advanced ARC

NCT00000679
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
25
States / cities
Harbor City, California • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Not applicable Interventional

An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients

NCT00002266
View directory record Official record
Conditions
HIV Infections
Interventions
AS-101
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Not applicable Interventional

A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3

NCT00000844
View directory record Official record
Conditions
HIV Infections
Interventions
Interferon alfa-n3, Interferon alfa-n1
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
15
States / cities
Los Angeles, California • Redwood City, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

NCT00000829
View directory record Official record
Conditions
HIV Infections, Pneumococcal Infections
Interventions
Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 6 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
31
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 18, 2026, 4:09 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Short Arc Multifidus Study

NCT00846664
View directory record Official record
Conditions
Multifidus Disuse Atrophy
Interventions
Logan Short Arc Banding
Procedure
Lead sponsor
Logan College of Chiropractic
Other
Eligibility
18 Years to 54 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 19, 2009 · Synced Oct 18, 2026, 4:09 AM EDT
Recruiting Phase 1Phase 2 Interventional

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

NCT07579195
View directory record Official record
Conditions
Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
Interventions
Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent, Radical Cystectomy, Pelvic Lymphadenectomy, Stereotactic Body Radiation Therapy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Transurethral Resection of Bladder Tumor, Cystoscopy, Biospecimen Collection, Questionnaire Administration
Radiation · Drug · Procedure + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Not applicable Interventional

A Study of Azidothymidine Plus Methadone in Patients With AIDS and AIDS Related Complex (ARC)

NCT00001008
View directory record Official record
Conditions
HIV Infections
Interventions
Methadone hydrochloride, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease

NCT00000626
View directory record Official record
Conditions
HIV Infections, Hodgkin's Disease
Interventions
Vinblastine sulfate, Dacarbazine, Filgrastim, Bleomycin sulfate, Doxorubicin hydrochloride
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Not applicable Interventional

The Effects of Zidovudine on the Blood of HIV-Infected Patients

NCT00000965
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 18, 2026, 4:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study

NCT01747746
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Thrombo-embolism, Bleeding
Interventions
Rivaroxaban, Warfarin and Enoxaparin
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Oct 18, 2026, 4:09 AM EDT